• Explore /
  • Poster
  • / Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

Abstract Poster

Authors

null

S. Leijen

Netherlands Cancer Institute, Amsterdam, Netherlands

S. Leijen , M. R. Middleton , P. Tresca , F. Kraeber-Bodere , V. Dieras , M. E. Scheulen , J. Tessier , Z. X. Xu , E. Shochat , A. Walz , J. Deutsch , S. Blotner , V. Lopez Valverde , V. M. Naegelen , J. H. M. Schellens , W. E. Eberhardt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Signal Transduction

Clinical Trial Registration Number

NCT00817518

Citation

J Clin Oncol 29: 2011 (suppl; abstr 3017)

Abstract #

3017

Poster Bd #

7

Abstract Disclosures

Similar Posters

First Author: Ben George

First Author: Rahul Raj Aggarwal

First Author: Philippe L. Bedard

First Author: Rahul Raj Aggarwal